Insider Selling: Belite Bio (NASDAQ:BLTE) CEO Sells $1,669,340.00 in Stock

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) CEO Yu-Hsin Lin sold 9,200 shares of Belite Bio stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $181.45, for a total transaction of $1,669,340.00. Following the transaction, the chief executive officer directly owned 170,934 shares of the company’s stock, valued at approximately $31,015,974.30. This trade represents a 5.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Belite Bio Stock Performance

Shares of NASDAQ BLTE opened at $168.76 on Thursday. The firm has a market cap of $6.74 billion, a PE ratio of -73.37 and a beta of -1.22. The firm has a fifty day moving average of $171.45 and a 200 day moving average of $144.43. Belite Bio, Inc. Sponsored ADR has a one year low of $53.60 and a one year high of $200.00.

Belite Bio (NASDAQ:BLTE) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.18. On average, equities analysts predict that Belite Bio, Inc. Sponsored ADR will post -1.17 EPS for the current fiscal year.

Institutional Investors Weigh In On Belite Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in BLTE. Caitong International Asset Management Co. Ltd boosted its stake in Belite Bio by 28,200.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 283 shares of the company’s stock worth $45,000 after purchasing an additional 282 shares during the last quarter. Bank of America Corp DE boosted its stake in Belite Bio by 28.1% during the 3rd quarter. Bank of America Corp DE now owns 1,171 shares of the company’s stock worth $87,000 after purchasing an additional 257 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Belite Bio during the 4th quarter worth $103,000. Persistent Asset Partners Ltd acquired a new stake in Belite Bio during the 4th quarter worth $108,000. Finally, GAMMA Investing LLC boosted its stake in Belite Bio by 11.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,758 shares of the company’s stock worth $130,000 after purchasing an additional 176 shares during the last quarter. Institutional investors and hedge funds own 0.53% of the company’s stock.

Key Stories Impacting Belite Bio

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and a $200 price target on BLTE, signaling continued analyst confidence despite forecast changes. HC Wainwright Reaffirms “Buy”
• Positive Sentiment: Belite reported an upside surprise on its March quarter results (EPS beat), which supports investor optimism around the business beat-and-build narrative. BLTE MarketBeat Profile
• Neutral Sentiment: HC Wainwright made a very small upward tweak to its Q1‑2026 EPS estimate (from -$0.71 to -$0.70), a data point that is unlikely to materially move the stock on its own. Analyst Note
• Neutral Sentiment: Institutional ownership remains very low (reported ~0.53%), and recent small institutional buys/sells are unlikely to drive major flows. Institutional Trading Details
• Neutral Sentiment: Analyst coverage is mixed: several buy/overweight targets above $200 offset a few hold/sell views — consensus remains a “Moderate Buy” with an average target ~ $202. Analyst Consensus
• Negative Sentiment: HC Wainwright cut its Q3, Q4 and FY‑2026 EPS forecasts (Q3 and Q4 revised down; FY2026 lowered from $1.89 to $1.62), which reduces near‑term earnings expectations and can pressure the stock. Analyst Estimate Cuts
• Negative Sentiment: Director Wan‑Shan Chen sold 1,100 shares (~$180 avg price) in early April; insider selling can be interpreted negatively by the market. Director Sale
• Negative Sentiment: Another insider, Hao‑Yuan Chuang, sold 6,200 shares — additional insider sales add to downward pressure on sentiment. Insider Sale by Hao‑Yuan Chuang
• Neutral Sentiment: Coverage pieces asking when Belite will be profitable provide context but no new catalyst; they may keep focus on timing of clinical progress and path to profitability. When Can We Expect A Profit?

Analysts Set New Price Targets

Several equities research analysts recently commented on BLTE shares. HC Wainwright reissued a “buy” rating and issued a $200.00 price target on shares of Belite Bio in a report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Belite Bio in a report on Tuesday, April 7th. Wall Street Zen raised shares of Belite Bio from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Morgan Stanley lifted their target price on shares of Belite Bio from $191.00 to $201.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 3rd. Finally, Needham & Company LLC set a $217.00 target price on shares of Belite Bio in a research note on Tuesday, March 3rd. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $202.33.

Belite Bio Company Profile

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.